About epoetin alfa
Erythropoiesis-stimulating agent
Used for
- Treats anemia caused by chronic kidney disease.
- Treats anemia in some people receiving chemotherapy.
- Reduces transfusion needs during certain surgeries.
Usual adult dose
Varies by condition and route. Chronic kidney disease: commonly 50–100 units/kg three times weekly; chemotherapy: commonly 40,000 units weekly.
Usual dose in children
Chronic kidney disease: commonly 50 units/kg three times weekly, adjusted by response.
Common side effects
- High blood pressure
- Headache
- Joint or muscle aches
- Blood clots
Important warnings
- Can cause serious blood clots, heart attack, or stroke, especially with high hemoglobin levels.
- Blood pressure may rise; uncontrolled high blood pressure is a contraindication.
- May worsen cancer outcomes in some settings; use only for approved indications.
- Rarely causes severe allergic reactions or pure red cell aplasia.
Pregnancy
Human pregnancy data are limited. Use when clearly needed; risks and benefits require clinical assessment.
Breastfeeding
It is unknown whether epoetin alfa passes into human milk. Consider clinical benefits and potential risks.
Interactions
- No major direct drug interactions are established.
- Blood pressure medicines may need adjustment if blood pressure rises.
- Iron deficiency can reduce response; iron treatment may be needed.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.